酒精性肝病

摘要/Abstract

摘要： 酒精性肝病(ALD)涵盖不同的疾病表型,从脂肪变到炎症(脂肪性肝炎)、纤维化,并最终在一部分患者中发展为肝硬化及其相关并发症。本文对2023年ALD在流行病学、危险因素、自然史、发病机制、诊断、治疗、预后评估及慢病管理等方面的主要进展做一总结,并突出戒酒管理对作为ALD病因因素和预后主要驱动因素干预的重要性。

关键词: 酒精性肝病, 肝硬化, 戒酒, 肝移植

高沿航. 酒精性肝病[J]. 肝脏, 2024, 29(1): 21-26.

[1] Aslam A, Kwo PY. Epidemiology and Disease Burden of Alcohol Associated Liver Disease[J]. J Clin Exp Hepatol,2023,13(1):88-102.
[2] Xu H, Xiao P, Zhang F, et al. Epidemic characteristics of alcohol-related liver disease in Asia from 2000 to 2020: A systematic review and meta-analysis[J]. Liver Int,2022 ,42(9):1991-1998.
[3] Wu M, Qin S, Tan C, et al. Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study[J]. BMC Med,2023,21(1):277.
[4] Ding C, Ng Fat L, Britton A, et al. Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease[J]. Nat Commun,2023,14(1):8041.
[5] Im PK, Wright N, Yang L,et al; China Kadoorie Biobank Collaborative Group. Alcohol consumption and risks of more than 200 diseases in Chinese men[J]. Nat Med,2023,29(6):1476-1486.
[6] Millwood IY, Im PK, Bennett D, et al; China Kadoorie Biobank Collaborative Group. Alcohol intake and cause-specific mortality: conventional and genetic evidence in a prospective cohort study of 512 000 adults in China[J]. Lancet Public Health,2023,8(12):e956-e967.
[7] Cho Y, Bukong TN, Tornai D, et al. Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis[J]. J Hepatol,2023,78(1):28-44.
[8] Khan RS, Lalor PF, Thursz M, et al. The role of neutrophils in alcohol-related hepatitis[J]. J Hepatol,2023,79(4):1037-1048.
[9] Solís-Mu?oz P, de la Flor-Robledo M, García-Ruíz I, et al. Mitochondrial respiratory chain activity is associated with severity, corticosteroid response and prognosis of alcoholic hepatitis[J]. Aliment Pharmacol Ther,2023,57(10):1131-1142.
[10] Fromenty B, Roden M. Mitochondrial alterations in fatty liver diseases[J]. J Hepatol,2023 ,78(2):415-429.
[11] Thiele M, Suvitaival T, Trošt K, et al; MicrobLiver Consortium; GALAXY Consortium. Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis[J]. Gastroenterology,2023,164(7):1248-1260.
[12] Aguilar-Bravo B, Ari?o S, Blaya D, et al. Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming[J]. J Hepatol,2023,79(3):728-740.
[13] Buch S, Innes H, Lutz PL,et al. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study[J]. Gut, 2023,72(2):381-391.
[14] Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease[J]. J Hepatol,2023,79(2):277-286.
[15] Nahon P, Bamba-Funck J, Layese R, et al; ANRS CO12 CirVir and CIRRAL groups. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis[J]. J Hepatol,2023,78(3):584-595.
[16] Tyson LD, Atkinson S, Hunter RW, et al. In severe alcohol-related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL-8 and micro-RNAs[J]. Aliment Pharmacol Ther,2023, 58(11-12):1217-1229.
[17] Theodoreson MD, Aithal GP, Allison M, et al. Extra-hepatic morbidity and mortality in alcohol-related liver disease: Systematic review and meta-analysis[J]. Liver Int,2023,43(4):763-772.
[18] Hagström H, Thiele M, Sharma R, et al. Cardiovascular Outcomes in Patients With Biopsy-proven Alcohol-related Liver Disease[J]. Clin Gastroenterol Hepatol,2023, 21(7):1841-1853.
[19] Gratacós-Ginès J, Bruguera P, Pérez-Guasch M, et al. Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a systematic review and meta-analysis[J]. Hepatology,2023.
[20] Germani G, Mathurin P, Lucey MR,et al. Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience[J]. J Hepatol,2023, 78(6):1130-1136.
[21] Sedki M, Kwong A, Bhargava M, et al. Alcohol Use in Liver Transplant Recipients With Alcohol-related Liver Disease: A Comparative Assessment of Relapse Prediction Models[J]. Transplantation,2023.
[22] Israelsen M, Madsen BS, Torp N, et al; GALAXY; MicrobLiver Consortia. Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Gastroenterol Hepatol,2023, 8(6):523-532.
[23] Louvet A, Labreuche J, Dao T, et al. Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial[J]. JAMA,2023,329(18):1558-1566.
[24] Forrest E, Bernal W. The Role of Prophylactic Antibiotics for Patients With Severe Alcohol-Related Hepatitis[J]. JAMA,2023,329(18):1552-1553.
[25] Juanola A, Ma AT, de Wit K, et al; LiverHope Investigators. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis[J]. Gut,2023,73(1):156-165.
[26] Elkrief L, Ganne-Carrié N, Manceau H, et al; CIRRAL group. Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis[J]. J Hepatol,2023,79(4):910-923.
[27] Hofer BS, Simbrunner B, Hartl L, et al. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis. Clin Gastroenterol Hepatol,2023, 21(9):2308-2317.

酒精性肝病

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邓优, 王琦, 赵红, 谢雯. 肝硬化患者复代偿的临床研究进展[J]. 肝脏, 2024, 29(1): 9-12.
[2]	吴雯玥, 孙亚朦, 尤红. 肝纤维化逆转:小进步尚待大突破[J]. 肝脏, 2024, 29(1): 13-15.
[3]	汪春雨, 冯丽娟, 王宇. 肝硬化的常见并发症与管理[J]. 肝脏, 2024, 29(1): 18-21.
[4]	诸葛宇征. 门静脉肝窦血管性疾病[J]. 肝脏, 2024, 29(1): 29-30.
[5]	刘哲睿, 翟兴冉, 邹正升. 药物性急性肝功能衰竭近况[J]. 肝脏, 2024, 29(1): 30-33.
[6]	向璐, 张利娟, 杨俊连, 张达利, 冯丹妮. 肝移植术后食管静脉曲张患者的临床特点与风险因素[J]. 肝脏, 2024, 29(1): 44-46.
[7]	林家福, 余婷, 张培林, 刘雪涛, 王丽恒. mNGS对肝硬化自发性腹膜炎患者的诊断与预后的临床应用价值[J]. 肝脏, 2024, 29(1): 64-67.
[8]	马驰, 杨涓, 郑盛. 肠道菌群与肝脏疾病研究进展[J]. 肝脏, 2024, 29(1): 113-116.
[9]	冉晓娟, 吴娴, 周文秀, 朱霞. 肝移植改善终末期肝病患者易栓症1例[J]. 肝脏, 2024, 29(1): 138-139.
[10]	何泽平, 宋方彬, 徐军明. 肝移植的新进展与挑战[J]. 肝脏, 2023, 28(9): 1015-1017.
[11]	王海强, 郑淑丹, 石璠, 赵梅, 郑丽红. 胆汁酸-微生态轴在肝硬化进展中的调节作用[J]. 肝脏, 2023, 28(9): 1119-1122.
[12]	熊号峰, 孙丽莹. 2023年亚太肝病学会肝脏疾病腹水管理指南介绍[J]. 肝脏, 2023, 28(8): 897-902.
[13]	伍婷, 唐奇远, 廖雪姣, 赖长祥, 何清. 肝硬化患者并发食管胃底静脉曲张破裂出血的危险因素及再出血防治[J]. 肝脏, 2023, 28(8): 903-906.
[14]	张家齐, 王再超, 杨家耀, 王晓梦, 赵玉. 慢性乙型肝炎肝硬化患者继发肝性脑病风险预测模型的构建与验证[J]. 肝脏, 2023, 28(8): 916-920.
[15]	饶晨怡, 李锋. 肝硬化难治性腹水的诊治进展[J]. 肝脏, 2023, 28(8): 987-989.